Centessa Q4 net loss widens to $111.3M; cash $482M; OX2R pipeline on track for 2025 data

Centessa Pharmaceuticals plc

Net loss $111.3M in Q4 2024 vs $36.8M Q4 2023, full-year loss $235.8M.
R&D expenses $60.9M Q4 2024 included $31.5M one-time charge from SerpinPC discontinuation.
Cash, equivalents and short-term investments $482.2M as of Dec 31, 2024; expected to fund into mid-2027.
ORX750 Phase 2a CRYSTAL-1 data in NT1, NT2, and IH expected in 2025; Phase 1 data showed restored wakefulness.
ORX142 and ORX489 advancing in IND-enabling studies with clinical data expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.